Paul Goodwin is a news writer for Cabot’s free e-newsletter, Wall Street’s Best Daily.
A researcher and writer for over 30 years, Paul brings a lifetime of inquiry to the task of figuring out whether stocks and markets are likely to go up or down. Prior to joining Cabot, Paul was a senior financial writer for Putnam Investments’ international and institutional communications, professor at the University of New Hampshire, and a Chinese linguist for the U.S. Army Security Agency.
In this week's video, Paul Goodwin, chief analyst of Cabot Global Stocks Explorer (formerly Cabot Emerging Markets Investor), doesn’t really talk about the markets at all. Rather, as he has for the past ten years, he reviews the year in verse, putting the and...
Read More
My three investing resolutions for 2019 are the same as they were for 2018 - even though the market climate has changed drastically over the last 12 months.
Read More
In this week's video, Paul Goodwin, chief analyst of Cabot Global Stocks Explorer (formerly Cabot Emerging Markets Investor), gives his thoughts on the market and looks at a few stocks that are performing better than the market. The trend is still down and is...
Read More
As Chinese stocks build a bottom, Alibaba and Baidu are two obvious buy-low Chinese ADR options. So let's look at BABA vs. BIDU. Which stock looks better?
Read More
Our second recommendation is a sale of a previous idea.
Read More
Analysts expect this technology company to grow 18.8% annually for the next five years.
Read More
Marijuana Prohibition is lifting. And that means it's time to buy marijuana stocks. This marijuana ETF is one way to play it. But I know a better way.
Read More
Want to know how to navigate market corrections like the current one? I have one very simple investing rule for you. And it applies to all situations.
Read More
Emerging market stocks and Chinese ADRs in particular have had a rough go in 2018. But these Chinese stocks are showing encouraging signs of life.
Read More
Moderation is a good way to live a healthy, balanced life. And moderation in growth investing is a good way to maintain a stable, profitable portfolio.
Read More
It's easy to get caught up in the latest stock market news. But the best way to invest is to tune out all the noise, and instead focus on this one thing.
Read More
In this week's video, Paul Goodwin, chief analyst of Cabot Global Stocks Explorer (formerly Cabot Emerging Markets Investor), talks about the November bounce that has followed the October flop of the markets. While the rally is welcome, it’s still not enough to create decisively...
Read More
Contrary to most other emerging markets - and many markets around the globe - Brazilian stocks have been on a tear of late. Here's how they've done it.
Read More
Emerging markets don't offer a ton of great buying options at the moment. But I do have a very good watch list stock for when the tide inevitably turns.
Read More
As a company, Tencent Holdings is doing everything right. Then why is Tencent Holdings stock struggling so much - and can it be salvaged?
Read More
Apple (AAPL) and Alibaba (BABA) are two blue chip stocks headed in two different directions. And therein lies the problem with buy-and-hold investing.
Read More
In this week's video, Paul Goodwin, chief analyst of Cabot Global Stocks Explorer (formerly Cabot Emerging Markets Investor), talks about the Thursday Massacre that hit the market this week. He also points out that the intermediate term trend of the market has turned Emerging...
Read More
Baidu, Alibaba and Tencent Holdings - a.k.a. the BAT stocks - have suffered from the trade war-fueled downturn in Chinese stocks. But the tide is turning.
Read More
Analysts have raised the 2018 earnings estimates of this Columbian oil company from $1.78 to $1.97 in the last 60 days.
Read More
In this week's video, Paul Goodwin, chief analyst of Cabot Global Stocks Explorer (formerly Cabot Emerging Markets Investor), talks about the generally positive market—while we've seen some hesitation this month (and could see more going forward), there remain relatively few signs of abnormal action plenty...
Read More
